Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Bo ZhangLing QiXi WangJianping XuYun LiuLan MuXingyuan WangLidan BaiJing HuangPublished in: Cancer communications (London, England) (2020)
This trial was registered on July 27, 2018, at ClinicalTrials.gov (identifier: NCT03603756).